Home > others & > Nile Red

Nile Red

Nile Blue A oxazone,Phenoxazone 9,Phenoxazone-9,Phenoxazone9,

Nile red是脂质定位和定量（主要是在含有中性脂质液滴的细胞）。

目录号
EY2029
EY2029
EY2029
纯度
99.08%
99.08%
99.08%
规格
5 mg
10 mg
50 mg
原价
220
380
620
售价
220
380
620
库存
现货
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Nile red is used to localize and quantitate lipids, particularly neutral lipid droplets within cells. Nile red is almost nonfluorescent in water and other polar solvents but undergoes fluorescence enhancement and large absorption and emission blue shifts in nonpolar environments (excitation/emission maxima ~552/636 nm in methanol).

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Greenspan P, et al. Nile red: a selective fluorescent stain for intracellular lipid droplets. J Cell Biol. 1985 Mar;100(3):965-73.
    [2] So-Yeon Park, et al. Near-infrared solid-state fluorescent naphthooxazine dyes attached with bulky dibutylamino and perfluoroalkenyloxy groups at 6- and 9-positions. Tetrahedron Letters 50: 1131-1135.
    [3] Fowler SD, et al. Application of Nile red, a fluorescent hydrophobic probe, for the detection of neutral lipid deposits in tissue sections: comparison with oil red O. J Histochem Cytochem. 1985 Aug;33(8):833-6.

    分子式
    C20H18N2O2    		 分子量
    7385-67-3    		 CAS号
    7385-67-3    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    10 mM    		 Water
    <1 mg/mL    		 Ethanol
    <1 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT01420328 Inflammation Drug: Vytorin Kaleida Health Phase 3 2011-05-01 2012-12-17
    NCT00097006 Acquired Immunodeficiency Syndrome|Blood Donors|Blood Transfusion|HIV Infections|HIV-1|HIV-2|HTLV-I|HTLV-II|Retroviridae Infections|Hepatitis, Viral, Human|Hepatitis B|Hepacivirus|West Nile Virus National Heart, Lung, and Blood Institute (NHLBI) 2004-09-01 2016-04-14
    NCT00049517 Leukemia Biological: sargramostim|Drug: busulfan|Drug: cyclophosphamide|Drug: cytarabine|Drug: gemtuzumab ozogamicin (GO)|Drug: Daunorubicin|Procedure: Autologous HCT|Procedure: Allogeneic HCT Eastern Cooperative Oncology Group|National Cancer Institute (NCI) Phase 3 2002-12-01 2016-12-01
    NCT00060398 Anemia|Fatigue|Prostate Cancer Biological: epoetin alfa|Drug: dexamethasone Eastern Cooperative Oncology Group|National Cancer Institute (NCI) Phase 3 2004-06-01 2009-05-09
    NCT00433511 Estrogen Receptor Negative|Estrogen Receptor Positive|HER2/Neu Negative|Male Breast Carcinoma|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer Biological: Bevacizumab|Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Paclitaxel|Other: Placebo|Other: Quality-of-Life Assessment National Cancer Institute (NCI)|Cancer and Leukemia Group B|Eastern Cooperative Oncology Group|North Central Cancer Treatment Group Phase 3 2009-12-01 2016-09-30
    NCT02965378 Recurrent Squamous Cell Lung Carcinoma|Stage IV Squamous Cell Lung Carcinoma Drug: FGFR Inhibitor AZD4547|Other: Laboratory Biomarker Analysis Southwest Oncology Group|National Cancer Institute (NCI) Phase 2|Phase 3 2014-06-01 2016-11-14
    NCT02785952 Recurrent Squamous Cell Lung Carcinoma|Stage IV Squamous Cell Lung Carcinoma Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Biological: Nivolumab Southwest Oncology Group|National Cancer Institute (NCI) Phase 3 2015-12-01 2017-03-03
    NCT02785939 Recurrent Squamous Cell Lung Carcinoma|Stage IV Squamous Cell Lung Carcinoma Other: Laboratory Biomarker Analysis|Drug: Palbociclib Southwest Oncology Group|National Cancer Institute (NCI) Phase 2|Phase 3 2014-06-01 2017-01-31
    NCT02785913 Recurrent Squamous Cell Lung Carcinoma|Stage IV Squamous Cell Lung Carcinoma Other: Laboratory Biomarker Analysis|Drug: Taselisib Southwest Oncology Group|National Cancer Institute (NCI) Phase 2 2014-06-01 2017-01-31
    NCT02766335 Recurrent Squamous Cell Lung Carcinoma|Stage IV Squamous Cell Lung Carcinoma Drug: Docetaxel|Biological: Durvalumab|Other: Laboratory Biomarker Analysis Southwest Oncology Group|National Cancer Institute (NCI) Phase 2 2014-06-01 2016-12-16
    NCT02154490 Recurrent Squamous Cell Lung Carcinoma|Stage IV Squamous Cell Lung Carcinoma Drug: Docetaxel|Biological: Durvalumab|Drug: Erlotinib Hydrochloride|Drug: FGFR Inhibitor AZD4547|Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Drug: Palbociclib|Biological: Rilotumumab|Drug: Taselisib Southwest Oncology Group|National Cancer Institute (NCI) Phase 2|Phase 3 2014-06-01 2017-03-03
    NCT01674140 Breast Cancer Drug: anastrozole|Drug: everolimus|Drug: exemestane|Drug: goserelin acetate|Drug: letrozole|Drug: leuprolide acetate|Drug: tamoxifen citrate|Other: placebo Southwest Oncology Group|National Cancer Institute (NCI) Phase 3 2013-04-01 2017-02-23
    NCT00843882 Anemia|Chronic Myelomonocytic Leukemia|de Novo Myelodysplastic Syndrome|Previously Treated Myelodysplastic Syndrome Biological: Epoetin Alfa|Other: Laboratory Biomarker Analysis|Drug: Lenalidomide National Cancer Institute (NCI) Phase 3 2009-01-01 2017-03-27
    NCT00769379 Ductal Breast Carcinoma In Situ|HER2/Neu Positive Other: Laboratory Biomarker Analysis|Biological: Trastuzumab|Radiation: Whole Breast Irradiation National Cancer Institute (NCI) Phase 3 2008-11-01 2017-03-27
    NCT00324805 Stage IB Non-Small Cell Lung Carcinoma|Stage IIA Non-Small Cell Lung Carcinoma|Stage IIB Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer Biological: Bevacizumab|Drug: Cisplatin|Drug: Docetaxel|Drug: Gemcitabine Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Pemetrexed Disodium|Other: Questionnaire Administration|Drug: Vinorelbine Tartrate National Cancer Institute (NCI)|Cancer and Leukemia Group B|NCIC Clinical Trials Group|North Central Cancer Treatment Group|Southwest Oncology Group Phase 3 2007-06-01 2017-03-27
    NCT00217737 Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Lynch Syndrome|Stage IIA Colon Cancer|Stage IIB Colon Cancer|Stage IIC Colon Cancer Biological: Bevacizumab|Drug: Fluorouracil|Other: Laboratory Biomarker Analysis|Drug: Leucovorin Calcium|Drug: Oxaliplatin National Cancer Institute (NCI) Phase 3 2005-08-01 2016-12-30
    NCT00738881 Recurrent Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer Drug: Erlotinib Hydrochloride|Drug: Pemetrexed Disodium National Cancer Institute (NCI)|Cancer and Leukemia Group B|Eastern Cooperative Oncology Group|NCIC Clinical Trials Group|Southwest Oncology Group Phase 3 2008-10-01 2015-10-06
    NCT00326898 Stage I Renal Cell Cancer|Stage II Renal Cell Cancer|Stage III Renal Cell Cancer Other: Placebo|Drug: Sorafenib|Drug: Sunitinib National Cancer Institute (NCI)|ECOG-ACRIN Cancer Research Group|NCIC Clinical Trials Group|Southwest Oncology Group|Cancer and Leukemia Group B Phase 3 2006-04-01 2016-12-15
    NCT00310180 Breast Adenocarcinoma|Estrogen Receptor and/or Progesterone Receptor Positive|HER2/Neu Negative|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIB Breast Cancer Drug: Anastrozole|Drug: Exemestane|Other: Laboratory Biomarker Analysis|Drug: Letrozole|Other: Quality-of-Life Assessment|Radiation: Radiation Therapy|Drug: Tamoxifen Citrate National Cancer Institute (NCI)|American College of Surgeons|Cancer and Leukemia Group B|NSABP Foundation Inc|NCIC Clinical Trials Group|North Central Cancer Treatment Group|Southwest Oncology Group Phase 3 2006-04-01 2017-03-27
    NCT00070499 Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Phase of Disease Drug: Dasatinib|Drug: Imatinib Mesylate|Other: Laboratory Biomarker Analysis National Cancer Institute (NCI) Phase 2 2004-08-01 2017-02-02
    NCT00785291 Estrogen Receptor Negative|Estrogen Receptor Positive|HER2/Neu Negative|HER2/Neu Positive|Male Breast Carcinoma|Progesterone Receptor Negative|Progesterone Receptor Positive|Recurrent Breast Carcinoma|Stage IIIC Breast Cancer AJCC v6|Stage IV Breast Cancer Drug: Paclitaxel|Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Drug: Ixabepilone|Biological: Bevacizumab|Other: Questionnaire Administration|Other: Laboratory Biomarker Analysis National Cancer Institute (NCI) Phase 3 2008-10-01 2016-11-14
    NCT00024102 Breast Cancer Drug: Standard Treatment|Drug: capecitabine Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|NCIC Clinical Trials Group Phase 3 2001-09-01 2016-07-12
    NCT00006237 Melanoma (Skin) Biological: interleukin-2|Biological: filgrastim|Biological: interferon alfa|Drug: cisplatin|Drug: dacarbazine|Drug: vinblastine Southwest Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Cancer and Leukemia Group B|Children's Oncology Group Phase 3 2000-08-01 2015-03-05
    NCT02465060 Advanced Malignant Neoplasm|Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Plasma Cell Myeloma|Refractory Malignant Neoplasm|Refractory Plasma Cell Myeloma Drug: Afatinib|Drug: Akt inhibitor AZD5363|Drug: Binimetinib|Drug: Crizotinib|Other: Cytology Specimen Collection Procedure|Drug: Dabrafenib|Drug: Dasatinib|Drug: Defactinib|Drug: FGFR Inhibitor AZD4547|Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Drug: Osimertinib|Drug: Palbociclib|Biological: Pertuzumab|Drug: PI3K-beta Inhibitor GSK2636771|Drug: Sapanisertib|Drug: Sunitinib Malate|Drug: Taselisib|Drug: Trametinib|Biological: Trastuzumab Emtansine|Drug: Trk Inhibitor LOXO-101|Drug: Vismodegib|Drug: WEE1 Inhibitor AZD1775 National Cancer Institute (NCI) Phase 2 2015-08-01 2017-03-27
    NCT02201992 Stage IB Non-Small Cell Lung Carcinoma|Stage IIA Non-Small Cell Lung Carcinoma|Stage IIB Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer Drug: Crizotinib|Other: Laboratory Biomarker Analysis|Other: Placebo ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group Phase 3 2014-08-01 2016-03-08

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：